Navigation Links
Bionovo Announces 2011 Highlights and Year-End Financial Results
Date:3/30/2012

g, if consummated, will change.  There can be no assurance as to the availability or terms upon which such financing and capital might be available. If we are not successful in our efforts to raise additional funds by April 15, 2012, we may be required to further delay, reduce the scope of, or eliminate one or more of our development programs or discontinue operations altogether.  

Key Events and Milestones

  • The Company initiated the first of two pivotal Phase 3 studies for its drug Menerba (MF101) for the treatment of menopausal hot flashes. The trial involving 50 clinical sites in the U.S. is a randomized, double blind, placebo controlled study planned for 1,200 menopausal women suffering from 50 or more moderate to severe hot flashes per week.  Due to financial constraints, enrollment of the trial has been voluntarily suspended after 280 patients.
  • The Company successfully completed a 28-day tolerability trial of Menerba in women investigating higher doses. As expected, there were no safety concerns, no reports of serious adverse events, no changes to blood pressure, heart rate or lab values and no cases of abnormal uterine findings on endometrial biopsies.  A dosing strategy was established for the Phase 3 study.
    In addition, in this same study, the Company reported an observed robust clinical effect of Menerba to reduce hot flashes after just 4 weeks of treatment. After 4 weeks of treatment with Menerba at 10g/day, the reduction in moderate to severe hot flashes was 69% (with a p value of 0.003). In addition, there was a 68% reduction in the number of nighttime awakenings due to hot flashes (with a p value of 0.001). The Menerba 10g/day dose used in this study has twice the potency compared to the highest dose tested in our Phase 2 study. This level of efficacy at 4 weeks is equivalent to or superior to es
    '/>"/>

  • SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
    2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
    3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
    4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
    5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
    6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
    7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
    8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
    9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
    10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
    11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/18/2014)... 18, 2014 Respiratory Motion and IMI Co ... device and services providers in Japan ... Motion,s innovative respiratory depression monitor, the ExSpiron™. As part ... working together to connect the clinical community in promoting ... of bringing innovative medical devices and new technology to ...
    (Date:11/18/2014)... SAN DIEGO , Nov. 18, 2014 ... stage biopharmaceutical company that discovers, develops and plans ... announced today that it filed an Investigational New ... Drug Administration (FDA) on Friday, November 14, 2014.  ... clinical development of a patented formulation of the ...
    (Date:11/18/2014)... -- BioLink 2015, the BioPh & ICSE BioPharm ... CCCMHPIE ( China Chamber of Commerce for ... UBM Live and Beijing Yizhuang Biomedical Park, will ... Yizhuang Biomedical Park.   ... will gather 200+ decision makers from biopharmaceutical industrial players ...
    Breaking Medicine Technology:Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4HedgePath Pharmaceuticals Files IND Application 2HedgePath Pharmaceuticals Files IND Application 3HedgePath Pharmaceuticals Files IND Application 4BioLink 2015 Will be Held on Jan 22, 2015, with a Focus on Biopharma Industrial Innovation & International Technology Transfer 2BioLink 2015 Will be Held on Jan 22, 2015, with a Focus on Biopharma Industrial Innovation & International Technology Transfer 3
    ... for This Common and Successful Surgery, ROCHESTER, ... September issue of Mayo Clinic Health Letter. You ... Reprinting is allowed for a,fee. Mayo Clinic Health ... as your editorial policies permit: Visit, http://www.HealthLetter.MayoClinic.com ...
    ... for older hip patients, ROSEMONT, Ill., Sept. ... rest of the Western population continue to age, ... serious concern for patients, families, and,healthcare systems. Elderly ... but the extremely elderly hip fracture patient may,face ...
    Cached Medicine Technology:September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 2September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 3September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 4Video: Prognosis Split for Hip Fracture and Hip Replacement in the Elderly 2
    (Date:11/21/2014)... CA (PRWEB) November 21, 2014 ... creating picture-perfect smiles for patients in preparation for the ... to the fronts of teeth, look completely natural, and ... certain situations, veneers are also valued for their ability ... patients and can be used on one or several ...
    (Date:11/21/2014)... say they,ve mapped the genome -- the genetic "blueprint" -- ... hopes it might help others with this very rare infection. ... Biology , the tapeworm was removed from the brain of ... is so rare worldwide and completely unexpected in this country ... was pulled out from the brain," study lead author Hayley ...
    (Date:11/21/2014)... The Ohio Children’s Trust Fund has agreed to ... of Pediatrics (Ohio AAP, [http://www.ohioaap.org ) to raise ... caregivers throughout Ohio. The new contract, which began November ... to continue the campaign that originally started in 2013. ... to continue partnering with the Ohio AAP to provide ...
    (Date:11/21/2014)... Midway through the research period for the 2015 ... of Health Plans, preliminary data shows volatility in the ... is a comprehensive resource with enrollment data and contact ... 2015 edition will be available in February. ... Division, the company’s exclusive in-house research team, have identified ...
    (Date:11/21/2014)... CA (PRWEB) November 21, 2014 ... for the dental practice. It includes everything needed to ... , Procedure Coding with CDT , CDT 2015 codes ... from January 1, 2014 - December 31, 2014. Dental ... procedures and services on dental claims. There are significant ...
    Breaking Medicine News(10 mins):Health News:Los Angeles Porcelain Veneers Dentist, Dr. Kevin Sands, Now Creates Picture-Perfect Smiles for Patients for the Holiday Season 2Health News:Ick! Tapeworm Infecting Man's Brain Yields Genetic Secrets 2Health News:Ohio AAP and Ohio Children’s Trust Fund Continue Partnership for Safe Sleep Education Campaign 2Health News:Ohio AAP and Ohio Children’s Trust Fund Continue Partnership for Safe Sleep Education Campaign 3Health News:Data from Atlantic Information Services’s Forthcoming Directory Shows Volatility in U.S. Health Care Market 2Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2
    ... N.J. (September 9, 2010) Researchers from the John Theurer ... role in a study that led to the Food & ... treatment for metastatic melanoma. The FDA based its decision largely ... New England Journal of Medicine on August 19, ...
    ... Steven Reinberg HealthDay Reporter , THURSDAY, Sept. 9 ... goals for the amount of fruit and vegetables people should ... not even close to reaching those thresholds, health officials said ... Disease Control and Prevention, in 2009, 67.5 percent of adults ...
    ... By Kathleen Doheny HealthDay Reporter , THURSDAY, Sept. ... obesity throughout your life: Doing so may improve your chances of ... who are obese and diagnosed with colon cancer appear to face ... are at a healthy weight or merely overweight, a new study ...
    ... (NEEM) will open tomorrow in Riga, Latvia with prostate, ... the two-day meeting. "The discussion will focus on ... will present updates on a variety of subjects such ... results in radical prostatectomy, treatment options in high-risk non ...
    ... This release is available in French . ... published in The Journal of Sexual Medicine has ... sympathy to women,s chronic vulvovaginal pain may trigger more pain, ... Women who took part in the study, conducted by the ...
    ... News media and others interested in the chemical sciences ... of American Chemical Society (ACS) Webinars, focusing on how ... funding programs. Scheduled for Thursday, Sept. 16, from ... will feature Josephine Yuen, Ph.D., NSF Program Director, speaking ...
    Cached Medicine News:Health News:Promising treatment for metastatic melanoma 'fast tracked' by FDA 2Health News:Promising treatment for metastatic melanoma 'fast tracked' by FDA 3Health News:Most Americans Still Not Eating Enough Fruits, Veggies 2Health News:Most Americans Still Not Eating Enough Fruits, Veggies 3Health News:Obesity May Up Death Risk in Older Women With Colon Cancer 2Health News:Obesity May Up Death Risk in Older Women With Colon Cancer 3Health News:Romantic partner may play role in reducing vulvovaginal pain 2Health News:American Chemical Society Webinar focuses on NSF's small business funding programs 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: